GlaxoSmithKline plc (LON:GSK – Get Rating) has earned an average recommendation of “Hold” from the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is GBX 1,757.50 ($22.02).
Several research analysts have recently issued reports on the company. Jefferies Financial Group set a GBX 2,100 ($26.32) price target on GlaxoSmithKline in a research report on Wednesday, April 27th. Credit Suisse Group set a GBX 1,400 ($17.54) price target on GlaxoSmithKline in a research report on Thursday, April 28th. UBS Group set a GBX 1,790 ($22.43) price target on GlaxoSmithKline in a research report on Thursday, April 28th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,850 ($23.18) price objective on shares of GlaxoSmithKline in a research note on Thursday, May 26th. Finally, Deutsche Bank Rese… set a GBX 1,750 ($21.93) price objective on GlaxoSmithKline in a research note on Thursday, May 19th.
In related news, insider Charles Bancroft bought 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, March 23rd. The shares were acquired at an average price of GBX 2,114 ($26.49) per share, for a total transaction of £58,980.60 ($73,910.53).
The business also recently announced a dividend, which will be paid on Friday, July 1st. Investors of record on Thursday, May 19th will be issued a dividend of GBX 14 ($0.18) per share. The ex-dividend date is Thursday, May 19th. This represents a yield of 0.8%. GlaxoSmithKline’s payout ratio is presently 0.79%.
GlaxoSmithKline Company Profile (Get Rating)
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Stratasys Stock Forming a Tradeable Bottom
- It’s Time To Get Interested In Ethereum Again
- How to Invest in Water Stocks: A Tutorial for Investors
- Expedia Group: Recovering with the Travel Industry
- It’s Time To Grab The Lovesac Company By The Shorts
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.